ArticleBMC cancer2025

Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy).

Yingyi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.